menu
    • menu
    [{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"AL001","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AL001","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for AL001

    Menu

    AL001

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alector

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alector to Present New AL001 Data at AD/PD™ 2022

                            Details : AL001 is being studied in Phase 2 trial for the treatment of frontotemporal dementia patients with a C9orf72 mutation (FTD-C9orf72). FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alector

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK and Alector Announce Global Collaboration in Immuno-Neurology for Two Clinical Stage Monoclonal Antibodies

                            Details : GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : $700.0 million

                            July 02, 2021

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth